Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
6,735
archived clinical trials in
Psoriasis

A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Baker Allergy, Asthma and Dermatology Research Center
mi
from
Lake Oswego, OR
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Oregon Dermatology & Research Center
mi
from
Portland, OR
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Oregon Dermatology & Research Center
mi
from
Portland, OR
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Oregon Health and Science University
mi
from
Portland, OR
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Oregon Health and Science University
mi
from
Portland, OR
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
University of Pittsburgh Medical Center, Department of Dermatology
mi
from
Pittsburgh, PA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
University of Pittsburgh Medical Center, Department of Dermatology
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Clinical Partners, LLC
mi
from
Johnston, RI
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Clinical Partners, LLC
mi
from
Johnston, RI
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Rhode Island Hospital
mi
from
Providence, RI
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Rhode Island Hospital
mi
from
Providence, RI
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Office of John Michael Humeniuk, MD
mi
from
Greer, SC
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Office of John Michael Humeniuk, MD
mi
from
Greer, SC
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Radiant Research
mi
from
Greer, SC
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Radiant Research
mi
from
Greer, SC
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Health Concepts
mi
from
Rapid City, SD
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Health Concepts
mi
from
Rapid City, SD
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Rivergate Dermatology Clinical Research Center, PLLC
mi
from
Goodlettsville, TN
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Dermatology Associates of Knoxville, PC
mi
from
Knoxville, TN
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Dermatology Associates of Knoxville, PC
mi
from
Knoxville, TN
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Dermatology Research Associates
mi
from
Nashville, TN
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Dermatology Research Associates
mi
from
Nashville, TN
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Arlington Research Center
mi
from
Arlington, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Arlington Research Center
mi
from
Arlington, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Dermatology Treatment & Research Center, PA
mi
from
Dallas, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Dermatology Treatment & Research Center, PA
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Modern Research Associates
mi
from
Dallas, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Modern Research Associates
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Menter Dermatology Research Institute
mi
from
Dallas, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Center for Clinical Studies
mi
from
Houston, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Center for Clinical Studies
mi
from
Houston, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Suzanne Bruce & Associates, PA
mi
from
Houston, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Suzanne Bruce & Associates, PA
mi
from
Houston, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Office of Mark Lee, MD
mi
from
San Antonio, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Office of Mark Lee, MD
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Progressive Clinical Research
mi
from
San Antonio, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Progressive Clinical Research
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Stephen Miller MD
mi
from
San Antonio, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Stephen Miller MD
mi
from
San Antonio, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Center for Clinical Studies
mi
from
Webster, TX
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Center for Clinical Studies
mi
from
Webster, TX
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Virginia Clinical Research, Inc.
mi
from
Norfolk, VA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Rockwood Research Center
mi
from
Spokane, WA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Rockwood Research Center
mi
from
Spokane, WA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Wenatchee Valley Hospital and Clinics
mi
from
Wenatchee, WA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Mountain State Clinical Research
mi
from
Bridgeport, WV
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Mountain State Clinical Research
mi
from
Bridgeport, WV
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Madison Skin & Research, Inc.
mi
from
Madison, WI
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Madison Skin & Research, Inc.
mi
from
Madison, WI
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Springfield Clinic
mi
from
Springfield, IL
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Springfield Clinic
mi
from
Springfield, IL
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Dartmouth Hitchcock Medical Center/Norris Cotton Cancer Center
mi
from
Lebanon, NH
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
University of Pittsburgh Medical Center
mi
from
Pittsburgh, PA
Click here to add this to my saved trials
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  7/20/2016
Centro De Investigaciones Dermatologicas
mi
from
Caba,
A Long Term Study To Evaluate The Safety And Tolerability Of CP-690,550 For Patients With Moderate To Severe Chronic Plaque Psoriasis
A Phase 3, Multi-site, Open-label Study Of The Long Term Safety And Tolerability Of 2 Oral Doses Of Cp-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 7/20/2016
Centro De Investigaciones Dermatologicas
mi
from
Caba,
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Encino, CA
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Encino, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Granada Hills, CA
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Granada Hills, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Mission Viejo, CA
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Mission Viejo, CA
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Tampa, FL
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Tampa, FL
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Louisville, KY
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Ypsilanti, MI
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Ypsilanti, MI
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Bronx, NY
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Bronx, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
New York, NY
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
New York, NY
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Portland, OR
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Portland, OR
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Warwick, RI
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Warwick, RI
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Webster, TX
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Webster, TX
Click here to add this to my saved trials
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated:  8/1/2016
Research Site
mi
from
Surrey,
A Study to Evaluate the Safety of Lebrikizumab Compared to Topical Corticosteroids in Adult Patients With Atopic Dermatitis
AN OPEN-LABEL STUDY TO EVALUATE THE SAFETY OF LEBRIKIZUMAB COMPARED TO TOPICAL CORTICOSTEROIDS IN ADULT PATIENTS WITH PERSISTENT, MODERATE TO SEVERE ATOPIC DERMATITIS
Status: Enrolling
Updated: 8/1/2016
Research Site
mi
from
Surrey,
Click here to add this to my saved trials
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Hot Springs, AR
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Hot Springs, AR
Click here to add this to my saved trials
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Little Rock, AR
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Little Rock, AR
Click here to add this to my saved trials
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Santa Monica, CA
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Santa Monica, CA
Click here to add this to my saved trials
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
Alpharetta, GA
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
Alpharetta, GA
Click here to add this to my saved trials
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated:  8/1/2016
Clinical Research Facility
mi
from
East Windsor, NJ
A Study of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis.
A Randomized, Placebo-controlled Dose-ranging Pilot Study to Assess the Effect on Clinical Response, and the Safety and Tolerability of R3421 in Patients With Moderate to Severe Chronic Plaque Psoriasis
Status: Enrolling
Updated: 8/1/2016
Clinical Research Facility
mi
from
East Windsor, NJ
Click here to add this to my saved trials